Cormedix (NASDAQ: CRMD)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-22 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.220 | -0.180 | 0.0400 | ||||
REV | 7.636K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cormedix (NASDAQ: CRMD) through any online brokerage.
Other companies in Cormedix’s space includes: Satsuma Pharmaceuticals (NASDAQ:STSA), Marinus Pharma (NASDAQ:MRNS), Incannex Healthcare (NASDAQ:IXHL), Harrow Health (NASDAQ:HROW) and Anebulo Pharmaceuticals (NASDAQ:ANEB).
The latest price target for Cormedix (NASDAQ: CRMD) was reported by Needham on Friday, May 14, 2021. The analyst firm set a price target for 29.00 expecting CRMD to rise to within 12 months (a possible 657.18% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Cormedix (NASDAQ: CRMD) is $3.83 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Cormedix.
Cormedix’s Q2 earnings are confirmed for Monday, August 22, 2022.
There is no upcoming split for Cormedix.
Cormedix is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.